A detailed history of Lion Point Capital, LP transactions in Geron Corp stock. As of the latest transaction made, Lion Point Capital, LP holds 630,000 shares of GERN stock, worth $2.51 Million. This represents 7.68% of its overall portfolio holdings.

Number of Shares
630,000
Previous 630,000 -0.0%
Holding current value
$2.51 Million
Previous $2.67 Million 7.08%
% of portfolio
7.68%
Previous 5.72%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.1 - $5.09 $93,000 - $152,700
30,000 Added 5.0%
630,000 $2.67 Million
Q1 2024

May 15, 2024

BUY
$1.75 - $3.44 $1.05 Million - $2.06 Million
600,000 New
600,000 $1.98 Million

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.51B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Lion Point Capital, LP Portfolio

Follow Lion Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lion Point Capital, LP with notifications on news.